ClinicalTrials.gg
RecruitingNCT06430892Updated May 29, 2024

RAPID-POP a Randomized Controlled Trial

An interventional study of Primary Percutaneous Coronary Intervention (PPCI) in Myocardial Infarction, Acute, sponsored by National Institute of Cardiovascular Diseases, Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by National Institute of Cardiovascular Diseases, Pakistan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Myocardial Infarction with a site in Pakistan — 3 open to participants now, 5 under way, none of them phase 3. Myocardial Infarction · Pakistan.

Planned enrollment
4th of 16
400 · median 77
Started
2024
with 3 others
No phase
9 of 17
2 open now
Registered
13th of 17
by date
Lead sponsor
2 of 17
National Institute of Cardiovascular Diseases, Pakistan

Among the 17 studies in Myocardial Infarction with a site in Pakistan, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 with no phase, and was the 13th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 17 studies in Myocardial Infarction with a site in Pakistan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myocardial Infarction with a site in Pakistan, or all of them as a file.
02

Study summary

Efficacy of the Pressure Optimization Protocol (POP) versus Conventional Stent Deployment Strategy during Primary PCI: An Open Label Randomized Clinical Trial The investigators will compare conventional rapid stent inflation/deflation during primary PCI with higher pressure and prolonged duration of stent deployment

Study Hypothesis: The POP in stent deployment is superior to the conventional stent deployment approach with a significantly higher achievement of the TIMI III flow, significantly lesser occurrence of slow flow/no-reflow, and significantly higher rate of ST-Segment resolution during primary PCI.

Read the detailed description

Primary Objective The primary objective is to compare the rate of TIMI III flow achievement, slow flow/no-reflow, and ST-segment resolution between POP versus conventional stent deployment strategy during Primary PCI.

Secondary Objective The secondary objective is in-hospital outcome (to compare the rate of major adverse cardiovascular events (MACE) during hospitalization between POP versus conventional stent deployment strategy during Primary PCI.) Material and Methods Study design: An open-label randomized controlled trial (RCT) with blinded outcome assessment Setting: Cath Lab NICVD Karachi ,Hyderabad and Sukkur Duration of study: 6 months Stent Deployment Protocol: Patients will be randomly assigned to either POP or conventional stent deployment approach groups in 1:1 ratio using the block randomization method.

SAMPLE SIZE : 400 patients will be randomized into 2 groups with 1:1 Concealment: Allocation schema will remain accessible to the randomization and allocation team and will be communicated to the screening and recruitment team on a patient-on-patient basis.

Blinding: This will be an open-label study, however, the outcome assessment will be blinded. A de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed.

Immediately post-procedure, a de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed. All the patients will be followed at 30 days and incidence of MACE will be recorded.

In order to ensure the integrity and reliability of the data, all procedures and imaging assessments will be carried out by clinicians and technicians trained and standardized in the respective methodologies. Moreover, data will be stored in a secure, electronic database with restricted access to maintain patient confidentiality and data security. Regular data audits will be conducted to ensure accuracy and consistency throughout the trial.

Data Analysis:

Firstly, patient demographics and baseline clinical characteristics will be summarized using means and standard deviations for continuous variables and frequencies with percentages for categorical variables. Kaplan-Meier survival analysis will be used to determine the time-to-event data for outcomes such as target vessel failure, target vessel revascularization, cardiac death, and myocardial infarction. Log-rank tests will be employed to compare survival curves between the POP and Rapid I/D groups. Cox proportional hazards models will be used to compute hazard ratios (HRs) and their 95% confidence intervals (CIs) for each outcome of interest, adjusting for potential confounders.

For categorical outcomes, chi-squared tests or Fisher's exact tests will be used, as appropriate. Continuous outcomes will be assessed using t-tests or Mann-Whitney U tests based on data distribution. Any unmatched or imbalanced variables between the two groups will be controlled using propensity score matching. To address potential confounding factors and biases, a sensitivity analysis will be performed.

Lastly, all statistical analyses will be two-tailed, with a significance level set at p \< 0.05. Statistical software such as SPSS or R will be utilized for the analysis.

03

Conditions studied

  • Myocardial Infarction, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years and above.
  • Patients undergoing primary percutaneous coronary intervention (PCI) with stent implantation.
  • Presence of significant coronary artery stenosis (greater than 70% diameter reduction) confirmed by angiography.

Exclusion criteria

Exclusion Criteria:

  • Patients with Killip class IV
  • Patients with significant comorbidities such as end-stage renal disease or advanced liver disease which may interfere with the procedure or follow-up.
  • Prior history of coronary artery bypass grafting (CABG).
  • Refusal to give consent for study participation or procedure
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Other
    POP Protocol

    Patients in this arm will be treated according to the POP protocol for stent deployment

    Procedure: Primary Percutaneous Coronary Intervention (PPCI)

  • Other
    Conventional method

    Patients in this arm will be treated with conventional method (rapid inflation-deflation protocol) for stent deployment

    Procedure: Primary Percutaneous Coronary Intervention (PPCI)

Interventions

  • ProcedurePrimary Percutaneous Coronary Intervention (PPCI)

    Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment

06

What researchers measure

Primary outcomes

  1. TIMI III flow: TIMI III flow is defined as normal flow with complete filling of the distal vascular bed.

    To assess flow in the vessel after deployment of stent

    Time frame: periprocedurally (after stent deployment)

  2. Slow-flow/no-reflow

    To assess is there any Slow-flow/no-reflow phenomenon , which is TIMI flow grade \< 3 and as myocardial blushing grade (MBG) \< 2.

    Time frame: periprocedurally (after stent deployment)

  3. ST-segment resolution

    Assessment of ST-segment resolution , The electrocardiographic resolution of the ST-segment elevation is defined as a reduction of \> 50% of the ST-segment elevation in the same lead within 60 min after the index procedure

    Time frame: Time frame:60minutes after the procedure

Secondary outcomes

  1. Cardiovascular death ( CV death)

    cardiovascular death

    Time frame: Time frame: during hospitalization (in-hospital)

  2. Myocardial infarction

    Myocardial infarction of different territory

    Time frame: Time frame: during hospitalization (in-hospital)

  3. Stent thrombosis

    same territory Myocardial infarction

    Time frame: Time frame: during hospitalization (in-hospital)

  4. Cerebrovascular accident ( CVA /Stroke)

    Cerebrovascular events during hospital stay

    Time frame: Time frame: during hospitalization (in-hospital)

  5. Arrhythmias

    Significant arrhythmias requiring treatment

    Time frame: Time frame: during hospitalization (in-hospital)

07

Study locations

1 of 1 sites recruiting
  • National institute of cardiovascular diseases
    Karachi, Sindh 75510, Pakistan
    Recruiting
    • Shakir Zada, FELLOW · Principal investigator
    • HAROON ISHAQ, AP · Sub investigator
    • AYAZ MIR, AP · Sub investigator
    • FAIZA FAROOQ, AP · Sub investigator
    • ABDUL HAMEED, FELLOW · Sub investigator
    • FARAZ MEMON, AP · Sub investigator
    • HASSAN BUT, AP · Sub investigator
    • CHANDAR PARKASH, AP · Sub investigator
    • QAMAR ZAMAN, FELLOW · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Nov 2024, 6 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 6 months is below that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 28, 2024
StartActual
May 15, 2024
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430892
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
Responsible party
Professor Abdul Hakeem (professor, National Institute of Cardiovascular Diseases, Pakistan) — Principal investigator
First posted
May 28, 2024
Start date
May 15, 2024
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
May 29, 2024

Study contacts

Abdul Hakeem, professor
Contact
abdulhakeem@gmail.com
+923355554342
Shakir Zada, fellow
Contact
dr.shakir637@gmail.com
+923469467449
ABDUL HAKEEM, PROF
principal investigator · National Institute of Cardiovascular Diseases, Pakistan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion